Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany; HITBR Hector Institute for Translational Brain Research GmbH, Mannheim, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy; Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy.
Pharmacol Ther. 2020 Jun;210:107520. doi: 10.1016/j.pharmthera.2020.107520. Epub 2020 Mar 9.
While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.
虽然神经递质功能障碍是精神疾病的一个关键组成部分,但现在人们广泛认为存在一个包括激素、神经炎症、氧化还原机制以及氧化应激在内的核心病理生理学中心。关于氧化还原(redox)机制,临床前和临床证据表明,促氧化剂和抗氧化剂之间的平衡失调,导致具有氧化潜能的物质产生增加,可能导致不同精神疾病的病因和表现。大脑对能量的大量持续需求使其极易受到能量供应紊乱的影响,特别是在暴露于应激事件后,这可能导致抗氧化防御受到干扰时活性氧和氮物种的过度产生。这最终会导致不同的分子改变,包括广泛的蛋白质和脂质过氧化、血脑屏障通透性增加和神经炎症,这可能导致精神疾病中观察到的大脑功能和形态的变化。这种观点也可以调和精神疾病的不同关键概念,例如这些疾病的神经发育起源,以及对特定功能异常至关重要的选择性细胞群体的脆弱性。作为一种对抗大脑氧化机制失衡的有害影响的新治疗策略,药理学调节氧化还原系统的可能性正受到越来越多的关注。这篇综述将描述氧化还原系统的主要机制和介质,并检查精神疾病动物模型以及患有精神疾病(如精神分裂症和重度抑郁症)的患者中发现的氧化应激改变。此外,它还将讨论研究精神药物(包括抗精神病药和抗抑郁药)对氧化平衡的影响,以及研究直接调节氧化机制在对抗与精神疾病相关的行为和功能改变的有效性的研究,这支持了氧化还原系统作为一种新的治疗靶点,用于改善大脑疾病的治疗的有前途的作用。